Amylin's Byetta Faces Bigger Obstacles (RealMoney.com $)
The outlook for the diabetes drug worsens on side-effect worries and rising competition.
Related Topics: Fundamental Analysis | Drugs
02:15PM 09/02/08
Value vs. Risk in Pharma (RealMoney.com $)
There are plenty of pitfalls, but these stocks are cheap and offer a nice dividend.
Related Topics: Fundamental Analysis | Drugs
03:58PM 06/19/08
DGX Preview: It's All in the Guidance (RealMoney.com $)
Quest Diagnostics' outlook for 2008 is most likely going to be what investors will be interested in.
Related Topics: Biotech | Fundamental Analysis
04:59PM 02/20/08
Passing the BLUD Test (RealMoney.com $)
Immucor has had plenty of problems over the past year, but the time to get behind it may finally have come.
Related Topics: Fundamental Analysis | Biotech
10:04AM 02/20/08
Will Latest DNA Test Be Enough? (RealMoney.com $)
A recent Genentech trial may open the door for further use for Avastin, but it is not a foregone conclusion.
Related Topics: Fundamental Analysis | Biotech
12:29PM 02/13/08
Salvaging Buys From the Biohazard Bin (RealMoney.com $)
The basket includes tickers such as CAH, BSX and PDCO.
Related Topics: Drugs | Health Care | Insurance | Fundamental Analysis | Biotech
12:53PM 12/21/07
DNA Tests Positive (RealMoney.com $)
Genentech received some bad news on Avastin, but that doesn't mean the stock doesn't look good here.
Related Topics: Biotech | Fundamental Analysis
10:47AM 12/06/07
ESRX Releases Guidance (RealMoney.com $)
The higher targets should keep a floor under the stock.
Related Topics: Fundamental Analysis
09:18AM 11/27/07
10 Things to Watch in Big-Cap Health Care
Here are some companies and issues that could have an impact in 2007.
Related Topics: Health Care | Opinion
03:32PM 01/05/07
10 Things to Watch in Big-Cap Health Care (RealMoney.com $)
Here are some companies and issues that could have an impact in 2007.
Related Topics: Health Care | Drugs | Biotech | Market Commentary | Fundamental Analysis
03:21PM 01/05/07
Find more premium investing ideas